R&F Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

R&F Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.51M	Buy	+13,806	New	+$1.22M	0.39%	46

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

R&F Capital Advisors's VRTX Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2017: 13,806 shares worth $1.51M. The stake represents 0.39% of the portfolio and ranks #46 among its holdings.

522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

R&F Capital Advisors held 13,806 shares of Vertex Pharmaceuticals worth $1.51M as of Q1 2017.
Vertex Pharmaceuticals was a new R&F Capital Advisors position in Q1 2017.
Vertex Pharmaceuticals made up 0.39% of R&F Capital Advisors's portfolio in Q1 2017, its #46 holding.
522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.